Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. Founded by Omid Farokhzad and Stephen J. Lippard in 2012, Tarveda Therapeutics is backed by investors that include New Enterprise Associates, Versant Ventures, Novo Holdings, Flagship Pioneering, and NanoDimension and is headquartered in Watertown.